Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | lysophospholipase, putative | 0.00878945 | 0.5 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.00878945 | 0.5 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.00878945 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.00878945 | 0.5 | 0.5 |
Plasmodium falciparum | esterase, putative | 0.00878945 | 0.5 | 0.5 |
Mycobacterium ulcerans | lysophospholipase | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.00878945 | 0.5 | 0.5 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.00878945 | 0.5 | 0.5 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.00878945 | 0.5 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | valacyclovir hydrolase, putative | 0.00878945 | 0.5 | 0.5 |
Mycobacterium leprae | POSSIBLE LYSOPHOSPHOLIPASE | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.00878945 | 0.5 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.00878945 | 0.5 | 0.5 |
Plasmodium vivax | PST-A protein | 0.00878945 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible lysophospholipase | 0.00878945 | 0.5 | 0.5 |
Leishmania major | monoglyceride lipase, putative | 0.00878945 | 0.5 | 0.5 |
Trypanosoma cruzi | monoglyceride lipase, putative | 0.00878945 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.00878945 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 | > 10 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 0.02673 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | > 1.25 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.